肺动脉高压治疗新方法——内皮素受体A治疗性疫苗  

A new method for treatment of pulmonary arterial hypertension——a therapeutic vaccine targeting endothelin A receptor

作　　者：周子华[1] ZHOU Zi-hua(Department of Cardiology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China)

机构地区：[1]华中科技大学同济医学院附属协和医院心内科,武汉430022

出　　处：《中国临床新医学》2020年第9期859-862,共4页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：国家自然科学基金资助项目(编号:81770366,81470494)。

摘　　要：肺动脉高压(PAH)是一种慢性致死性疾病,现有针对PAH的药物虽有一定的治疗效果,但其预后仍不尽人意,需要探索新的治疗方法。治疗性疫苗是治疗PAH的新方法。内皮素(ET)系统,尤其是ET-1和内皮素受体A(ETAR)的异常激活与PAH的发病机制密切相关,ETAR是PAH治疗性疫苗的理想靶点。我们最近成功研发出一种以ETAR为靶点的PAH治疗性疫苗ETRQβ-002。该疫苗能显著降低两种PAH动物模型的肺动脉压,改善甚至逆转肺小动脉重构和右心室肥厚,且没有发现明显的靶器官免疫损害和肝肾功能异常,说明ETRQβ-002是一种能有效并且安全地治疗PAH的治疗性疫苗。Pulmonary arterial hypertension(PAH)is a chronic and fatal disease.Although the existing agents for PAH have certain therapeutic effects,their prognoses are still unsatisfactory,and new treatment methods need to be explored.Therapeutic vaccines offer a novel approach to treating PAH.The abnormal activation of endothelin(ET)system,especially ET-1 and endothelin A receptor(ETAR)is closely related to the pathogenesis of PAH,and ETAR is an ideal target of PAH therapeutic vaccine.Recently,we have successfully developed ETRQβ-002,a PAH therapeutic vaccine targeting ETAR,which can significantly reduce pulmonary artery pressure in two types of PAH-model animals,and improve or even reverse the remodeling of pulmonary arterioles and right ventricular hypertrophy,and no obvious target organ immune damage and abnormal liver and kidney function are found,indicating that ETRQβ-002 is an effective and safe therapeutic vaccine for PAH.

关 键 词：肺动脉高压 内皮素 内皮素受体A 治疗性疫苗 

分 类 号：R544.16[医药卫生—心血管疾病]